ATHINA MARKOU

ATHINA MARKOU


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Fertility and Sterility
Verified
Journal Article
Closed access
AMATHINA MARKOU
ATHINA MARKOU
IAIoannis I. Androulakis
Ioannis I. Androulakis
CMChristos Mourmouris
Christos Mourmouris
ATAgeliki Tsikkini
Ageliki Tsikkini
CSChristianna Samara
Christianna Samara
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas

10 June 2011 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
IAIoannis I. Androulakis
Ioannis I. Androulakis
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
AMATHINA MARKOU
ATHINA MARKOU
ETErmioni Tseniklidi
Ermioni Tseniklidi
PKParaskevi Kafritsa
Paraskevi Kafritsa
GPGeorge P. Piaditis
George P. Piaditis

8 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
NMNiki Mourtzi
Niki Mourtzi
ASAmalia Sertedaki
Amalia Sertedaki
AMATHINA MARKOU
ATHINA MARKOU
GPGeorge P. Piaditis
George P. Piaditis
Evangelia CharmandariEvangelia Charmandari
Evangelia Charmandari
Primary aldosteronism (PA), a condition characterized by autonomous aldosterone hypersecretion, constitutes the most common cause of secondary hypertension. Over the last decade, major breakthroughs have been made in the field of genetics underpinning PA. The advent and wide application of Next Generation Sequencing (NGS) technology led to the identification of several somatic and germline mutations associated with sporadic and familial forms of PA. Somatic mutations in ion-channel genes that participate in aldosterone biosynthesis, including KCNJ5, CACNA1D, ATP1A1, and ATP2B3, have been implicated in the development of aldosterone-producing adenomas (APAs). On the other hand, germline variants in CLCN2, KCNJ5, CACNA1H, and CACNA1D genes have been implicated in the pathogenesis of the familial forms of PA, FH-II, FH-III, and F-IV, as well as PA associated with seizures and neurological abnormalities. However, recent studies have shown that the prevalence of PA is higher than previously thought, indicating the need for an improvement of our diagnostic tools. Further research is required to recognize mild forms of PA and to investigate the underlying molecular mechanisms.

1 November 2011 in Endocrine Practice
Verified
Journal Article
Closed access
AMATHINA MARKOU
ATHINA MARKOU
VTVassiliki Tsiama
Vassiliki Tsiama
STSYMEON TOURNIS
SYMEON TOURNIS
LPLabrini Papanastasiou
Labrini Papanastasiou
VTVaios Tsiavos
Vaios Tsiavos
GPGeorge Piaditis
George Piaditis

29 July 2010 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
GZGeorge N Zografos
George N Zografos
TPTheodora Pappa
Theodora Pappa
SASpiros Avlonitis
Spiros Avlonitis
AMATHINA MARKOU
ATHINA MARKOU
DCDimosthenis Chrysikos
Dimosthenis Chrysikos
GPGeorge Piaditis
George Piaditis
Introduction: Primary pigmented nodular adrenocortical disease is a rare cause of adrenocorticotropic hormone-independent Cushing's syndrome. We report an uncommon primary pigmented nodular adrenocortical disease case presenting with a unilateral adrenocortical nodule and provide a brief overview of the existing literature. Case presentation: A 27-year-old Caucasian woman was admitted to our Department with adrenocorticotropic hormone-independent Cushing's syndrome. Its cause was initially considered a left adrenocortical adenoma based on computer tomography imaging. The patient underwent left laparoscopic adrenalectomy and histological examination revealed pigmented micronodular adrenal hyperplasia. Evaluation for the presence of Carney complex was negative. Six months later recurrence of hypercortisolism was documented and a right laparoscopic adrenalectomy was performed further establishing the diagnosis of primary pigmented nodular adrenocortical disease. After a nine-year follow-up there is no evidence of residual disease. Conclusions: Even though primary pigmented nodular adrenocortical disease is a rare cause of Cushing's syndrome, it should be included in the differential diagnosis of adrenocorticotropic hormone-independent Cushing's syndrome, especially because adrenal imaging can be misleading mimicking other adrenocortical diseases. Bilateral laparoscopic adrenalectomy is the preferred treatment in these subjects.

1 April 2012 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
TPTheodora Pappa
Theodora Pappa
LPLabrini Papanastasiou
Labrini Papanastasiou
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
AMATHINA MARKOU
ATHINA MARKOU
PTPanayiotis Tsounas
Panayiotis Tsounas
GPGeorge Piaditis
George Piaditis
Approximately 10% of hypertensives are considered to exhibit autonomous aldosterone secretion (AAS). Although adrenal incidentalomas (AI) can be found in up to 19% of hypertensive individuals, data on the incidence of AAS in hypertensive patients with AI remain scarce. The aim was to study adrenal aldosterone (ALD) secretory pattern in patients with adrenal adenomas with and without arterial hypertension. We conducted a case-control study in a tertiary general hospital. We investigated 72 normotensive subjects with normal adrenal morphology and 191 subjects divided in three groups: 46 normotensive individuals with an AI (NAI), 89 hypertensive patients with an AI (HAI), and 56 hypertensive patients with an adrenal adenoma identified after investigation for arterial hypertension (HAA). Evaluation of autonomous cortisol secretion was based on a low-dose dexamethasone suppression test. Autonomous ALD secretion was based on a modified saline infusion test (MSI). Normal cutoff levels were obtained from the control matched population. Post-MSI ALD levels and the ALD/renin (REN) ratios were significantly elevated in HAI and HAA patients compared to NAI subjects. To evaluate the prevalence of AAS, we applied the combination of post-MSI ALD level and the ALD/REN ratio simultaneously (post-MSI cutoffs, ALD levels, 2.41 ng/dl; ALD/REN ratio, 0.35 ng/dl/μU/ml). Based on these cutoffs, 12% of NAI, 36.4% of HAI, and 54.2% of HAA patients had AAS. The prevalence of autonomous cortisol secretion did not differ among the three groups. Using a MSI test, we found a remarkably increased prevalence of AAS in hypertensive patients with adrenal adenomas, even when the latter represented an incidental finding.